drugset / Trial / NCT03024580

A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer

NCT03024580

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This pilot trial evaluates in vivo megestrol acetate (MA) modulation of steroidal receptors in advanced breast cancer.

Timeline

Start
2017-03-06
Primary completion
2020-03
Completion
2020-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Anastrozole Other / unclassified 1 mg Oral
Comparator Exemestane Small molecule 25 mg Oral
Comparator Fulvestrant Small molecule 500 mg Intramuscular
Comparator Letrozole Other / unclassified 2.5 mg Oral
Subject Megestrol Acetate Other / unclassified 160 mg Oral
Comparator Tamoxifen Small molecule 20 mg Oral

Indications